Avalo Therapeutics
AVTX
21 hedge funds and large institutions have $9.6M invested in Avalo Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
2,944% more capital inflows, than outflows
Capital inflows: $9.08M | Capital outflows: $298K
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
17% more funds holding
Funds holding: 18 → 21 (+3)
7.05% more ownership
Funds ownership: 0.9% → 7.95% (+7%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
+$6.99M |
| 2 |
Sio Capital Management
New York
|
+$795K |
| 3 |
Commodore Capital
New York
|
+$519K |
| 4 |
Affinity Asset Advisors
New York
|
+$454K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ADAR1 Capital Management
Austin,
Texas
|
-$130K |
| 2 |
Natixis
Paris,
France
|
-$54.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$53.6K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$35.7K |
| 5 |
BlackRock
New York
|
-$23.3K |
AVTX Hedge Fund Activity: Q2 2024 in Review
21 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2024, worth a combined $9.6M — up 407% from $1.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new AVTX positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $6.99M. The largest seller was ADAR1 Capital Management, exiting entirely with an estimated $130K sold.
- 21 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2024, up from 18 in Q1 2024.
- Funds reported $9.6M of Avalo Therapeutics stock for Q2 2024, up 407% quarter-over-quarter.
- 7 funds opened new Avalo Therapeutics positions in Q2 2024 and 4 closed out, a net change of +3 holders.
- The largest Avalo Therapeutics buyer in Q2 2024 was Logos Global Management, an estimated $6.99M added.
- The largest Avalo Therapeutics seller in Q2 2024 was ADAR1 Capital Management, an estimated $130K sold.
Based on aggregated 13F filings for Q2 2024.